Skip to main content

Table 4 Influencing factors of reporting quality scores from Liner regression model

From: Were economic evaluations well reported for the newly listed oncology drugs in China’s national reimbursement drug list

Characteristic

Coefficients

SE

P value

Author numbers

1 ~ 3

Ref.

  

4 ~ 6

-1.555

1.665

0.354

> 7

-1.458

1.778

0.415

Published year

2009 ~ 2015

Ref.

  

2016 ~ 2018

1.065

1.662

0.524

2019 ~ 2021

3.678

1.643

0.029

Language

Chinese

Ref.

  

English

11.607

1.777

< 0.001

Method of economic evaluation

Cost-utility analysis

Ref.

  

Cost-effectiveness analysis

-4.165

3.506

0.240

Cost minimization analysis

-3.540

6.747

0.602

Study design

Prospective Study

Ref.

  

Retrospective Study

-4.331

4.250

0.312

Modeling Study

2.555

5.139

0.621

Source of funding

No funding

Ref.

  

Governmenta

0.990

1.830

0.591

Pharmaceutical company

0.859

2.281

0.708

Not mentioned

-4.469

2.035

0.032

Study Perspective

Health insurance system

Ref.

  

Healthcare system

0.405

1.504

0.789

Societal

-4.639

2.002

0.024

Patient

4.001

2.946

0.180

Health Care Provider

-5.073

5.223

0.335

Not mentioned

-11.173

3.435

0.002

Time horizon

Not mentioned

Ref.

  

< 1 year

-3.706

5.541

0.506

1–5 year

1.618

2.120

0.448

6–10 year

0.470

2.223

0.833

> 10 year

2.427

2.454

0.327

Constant

 

67.686

5.808

< 0.001

  1. SE Standard error
  2. a Including other government-funded institutions, such as public hospitals